Evidence map›Paper›PMID 37112976›Full record

ReviewViruses2023

Evidence for Benefits of Early Treatment Initiation for Chronic Hepatitis B.

Young-Suk Lim, W Ray Kim, Douglas Dieterich, Jia-Horng Kao, John F Flaherty, Leland J Yee, Lewis R Roberts, Homie Razavi, Patrick T F Kennedy

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Viruses, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
6.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.

  1. [Interpretation of key updates of the 2026 version of the APASL clinical practice guidelines for the management of chronic hepatitis B].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026
    Guideline
  2. Article
  3. [APASL clinical practice guidelines on the management of chronic hepatitis B infection: a 2026 update].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026
    Article
  4. Article
  5. Indeterminate Phase/Grey Zone of Chronic Hepatitis B: Clinical Features, Outcomes and Molecular Insights.Liver international : official journal of the International Association for the Study of the Liver · 2026
    Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Progress towards "The Treat-All Approach" for hepatitis B.Translational gastroenterology and hepatology · 2025
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. [A new concept from a global perspective for expanding the treatment of chronic hepatitis B].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2024
    Article
  19. Article
  20. [Progress on the research of liver diseases in 2023].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 8 institutions in 4 countries.

Young-Suk LimDepartment of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Republic of Korea.ORCID 0000-0002-1544-577X
W Ray KimDivision of Gastroenterology and Hepatology, Stanford University School of Medicine, Palo Alto, CA 94063, USA.ORCID 0000-0002-3030-860X
Douglas DieterichDivision of Liver Diseases, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Jia-Horng KaoDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Department of Medical Research, Hepatitis Research Center, National Taiwan University Hospital, Taipei 100, Taiwan.ORCID 0000-0002-2442-7952
John F FlahertyGilead Sciences, Foster City, CA 94404, USA.
Leland J YeeGilead Sciences, Foster City, CA 94404, USA.ORCID 0000-0002-0369-5878
Lewis R RobertsDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA.ORCID 0000-0001-7885-8574
Homie RazaviCenter for Disease Analysis Foundation, Lafayette, CO 80026, USA.ORCID 0000-0002-2658-6930
Patrick T F KennedyBarts Liver Centre, Immunobiology, Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London E1 4NS, UK.ORCID 0000-0001-9201-0094
Gilead Sciences (United States) · USCenter for Disease Analysis · USIcahn School of Medicine at Mount Sinai · USMayo Clinic in Arizona · USNational Taiwan University · TWQueen Mary University of London · GBStanford University · USUlsan College · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic hepatitis B (CHB) is the most common cause of hepatocellular carcinoma (HCC) worldwide. Antiviral treatment reduces the risk of HCC and mortality; nonetheless, globally in 2019, only 2.2% of CHB patients received treatment. Current international CHB guidelines recommend antiviral treatment only in subsets of patients with clear evidence of liver damage. This contrasts with hepatitis C or HIV where early treatment is recommended in all infected patients, regardless of end-organ damage. This narrative review aims to provide an overview of data on the early initiation of antiviral treatment and its related potential economic impact. Literature searches were performed using PubMed and abstracts from international liver congresses (2019-2021). Data on risk of disease progression and HCC and the impact of antiviral treatment in currently ineligible patients were summarized. Cost-effectiveness data on early antiviral treatment initiation were also collated. Accumulating molecular, clinical, and economic data suggest that early initiation of antiviral treatment could save many lives through HCC prevention in a highly cost-effective manner. In light of these data, we consider several alternative expanded treatment strategies that might further a simplified 'treatment as prevention' approach.

Indexed as

Carcinoma, HepatocellularHepatitis B, ChronicLiver NeoplasmsAntiviral AgentsHepatitis B virusHumansAntiviral Agentscirrhosishepatitis Bhepatocellular carcinomaliver fibrosisviral hepatitis

Identifiers

PMID37112976
PMCPMC10142077
OpenAlexW4366420387

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.